Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent urinary tract infections in primary care: a qualitative study of women's experiences.

BMC primary care·2026
Same author

Risk of recurrent ischemic stroke after non-cardioembolic ischemic stroke in England and Denmark.

Journal of neurology·2026
Same author

Preventive strategies for recurrent urinary tract infections in premenopausal women: A scoping review.

The European journal of general practice·2026
Same author

Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU Experience.

Clinical epidemiology·2026
Same author

Estimating cost savings from reducing antibiotic overprescription in european general practices.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same author

Correction: Appropriateness of antibiotic use in nursing homes for suspected urinary tract infections: comparison across five European countries.

European geriatric medicine·2025

Related Experiment Videos

Hormone therapy and cerebrovascular events: a population-based nested case-control study.

Alejandro Arana1, Cristina Varas, Antonio González-Pérez

  • 1Novartis, Clinical Safety and Epidemiology, Madrid, Spain.

Menopause (New York, N.Y.)
|September 2, 2006
PubMed
Summary

Postmenopausal hormone therapy (HT) use is associated with a small increased risk of cerebrovascular events, particularly transient ischemic attacks (TIAs). The risk is dose-dependent, with higher estrogen doses showing a greater risk for TIAs.

Related Experiment Videos

Area of Science:

  • Neurology
  • Epidemiology
  • Women's Health

Background:

  • Conflicting results exist regarding the link between postmenopausal hormone therapy (HT) and cerebrovascular disease.
  • Previous studies and clinical trials have yielded inconsistent findings on this association.

Purpose of the Study:

  • To evaluate the association between hormone therapy (HT) use and the incidence of first cerebrovascular events.
  • To investigate the specific risks of transient ischemic attack (TIA), ischemic stroke, and hemorrhagic stroke in relation to HT.

Main Methods:

  • A nested case-control analysis was conducted using a cohort of 158,031 women aged 50-69 from the U.K. General Practice Research Database (1991-1997).
  • The study identified 920 confirmed cerebrovascular events (536 TIAs, 259 ischemic strokes, 125 hemorrhagic strokes) and 10,000 controls.

Main Results:

  • Current HT users showed an increased odds ratio for TIA (1.48), ischemic stroke (1.12), and hemorrhagic stroke (1.21) compared to never users.
  • The overall risk estimate for any cerebrovascular event was 1.34.
  • A significantly higher risk of TIA (1.96) was observed among women using high-dose estrogen therapy.

Conclusions:

  • Hormone therapy (HT) use is associated with a small increased risk of cerebrovascular events, consistent with recent clinical trial findings.
  • The elevated risk is more pronounced for transient ischemic attacks (TIAs) than for strokes.
  • Higher doses of HT appear to correlate with a greater risk of cerebrovascular events, particularly TIAs.